🔎 Trials Near Me

Почетна › Кронова болест › Luizijana

Kliničke studije za Кронова болест u državi Luizijana

11 studija za Кронова болест traži učesnike na lokacijama u državi Luizijana.

Gradovi u državi Luizijana

Zvanični tekst studije (na engleskom)

A Study of SL-325 in Crohn's Disease Patients

  • Clinical Trial Site, Houma
  • Clinical Trial Site, Marrero
Тражи се учесникФаза 2
Узраст од 18 до 80 · Оба пола · Ажурирано 12. 11. 2026. · NCT07753850

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Care Access - New Iberia, New Iberia
  • Louisiana Research Center, Shreveport
Тражи се учесникФаза 3
Узраст од 18 до 70 · Оба пола · Ажурирано 4. 11. 2026. · NCT06937099

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

  • Tandem Clinical Research, Houma
Тражи се учесникФаза 2
Узраст од 18 до 85 · Оба пола · Ажурирано 4. 11. 2026. · NCT06226883

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  • Gastroenterology Clinic of Acadiana, Lafayette
  • Delta Research Partners, LLC, West Monroe
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07196722

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  • Gastroenterology Clinic of Acadiana, Lafayette
  • GIA Metairie, Metairie
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07577843

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  • Gastroenterology Clinic of Acadiana, Lafayette
  • Louisiana State University Health Sciences Center Shreveport, Shreveport
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07499232

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

  • Baton Rouge General Medical Center - Bluebonnet Campus, Baton Rouge
  • Combined Gastro LLC, Lafayette
  • GI Alliance, Metairie
Тражи се учесникФаза 4
Узраст од 18 до 80 · Оба пола · Ажурирано 28. 10. 2026. · NCT06581328

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

  • Gastro Group and Endocenter: Mandeville, la /ID# 284186, Mandeville
  • Metropolitan Gastroenterology Associates - Metairie /ID# 283922, Metairie
  • Willis-Knighton Medical Center /ID# 280572, Shreveport
Тражи се учесникФаза 2
Узраст од 18 до 75 · Оба пола · Ажурирано 27. 10. 2026. · NCT07697456

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • GI Alliance - Baton Rouge-Site Number: 8400129, Baton Rouge
  • Texas Digestive Disease Consultants, PLLC d/b/a GI Alliance - Mandeville-Site Number: 8400128, Mandeville
  • GI Alliance - Metairie-Site Number: 8400124, Metairie
  • и још 1
Тражи се учесникФаза 3
Узраст од 16 до 80 · Оба пола · Ажурирано 21. 10. 2026. · NCT07184944

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • GI Alliance - Baton Rouge-Site Number: 8400129, Baton Rouge
  • Tandem Intermediate, LLC - Houma-Site Number: 8400034, Houma
  • Texas Digestive Disease Consultants, PLLC d/b/a GI Alliance - Mandeville-Site Number: 8400128, Mandeville
  • и још 4
Тражи се учесникФаза 3
Узраст од 16 до 80 · Оба пола · Ажурирано 21. 10. 2026. · NCT07184931

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

  • Mirador Therapeutics Selected Site, Lafayette
  • Mirador Therapeutics Selected Site, Marrero
  • Mirador Therapeutics Selected Site, Shreveport
Тражи се учесникФаза 2
Узраст од 18 до 80 · Оба пола · Ажурирано 12. 3. 2026. · NCT07113522

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.